Sign in or create an account to add this stock to your watchlist.
About Abbott Laboratories (NYSE:ABT)
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:ABT
CUSIP00282410
Phone224-667-6100
Debt
Debt-to-Equity Ratio0.67
Current Ratio1.66
Quick Ratio1.24
Price-To-Earnings
Trailing P/E Ratio24.95
Forward P/E Ratio21.81
P/E Growth1.78
Sales & Book Value
Annual Sales$27.39 billion
Price / Sales3.99
Cash Flow$4.8274 per share
Price / Cash12.92
Book Value$18.02 per share
Price / Book3.46
Profitability
EPS (Most Recent Fiscal Year)$2.50
Net Income$477 million
Net Margins1.67%
Return on Equity14.54%
Return on Assets6.34%
Miscellaneous
Employees99,000
Outstanding Shares1,753,190,000
Abbott Laboratories (NYSE:ABT) Frequently Asked Questions
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories declared a quarterly dividend on Friday, February 16th. Shareholders of record on Friday, April 13th will be given a dividend of $0.28 per share on Tuesday, May 15th. This represents a $1.12 dividend on an annualized basis and a yield of 1.80%. The ex-dividend date is Thursday, April 12th. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) released its quarterly earnings results on Wednesday, April, 18th. The healthcare product maker reported $0.59 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.58 by $0.01. The healthcare product maker earned $7.39 billion during the quarter, compared to analysts' expectations of $7.28 billion. Abbott Laboratories had a net margin of 1.67% and a return on equity of 14.54%. Abbott Laboratories's revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.48 EPS. View Abbott Laboratories' Earnings History.
When is Abbott Laboratories' next earnings date?
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories issued an update on its FY18 earnings guidance on Wednesday, April, 18th. The company provided earnings per share guidance of $2.80-2.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.86. Abbott Laboratories also updated its Q2 guidance to $0.70-0.72 EPS.
What price target have analysts set for ABT?
17 brokers have issued 1-year target prices for Abbott Laboratories' stock. Their predictions range from $56.00 to $80.00. On average, they expect Abbott Laboratories' share price to reach $68.4375 in the next year. View Analyst Ratings for Abbott Laboratories.
Are investors shorting Abbott Laboratories?
Abbott Laboratories saw a increase in short interest in April. As of April 30th, there was short interest totalling 14,602,527 shares, an increase of 52.8% from the April 13th total of 9,557,285 shares. Based on an average daily trading volume, of 6,737,663 shares, the short-interest ratio is currently 2.2 days. Approximately 0.8% of the shares of the company are short sold.
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Merck & Co. (MRK), Novo Nordisk A/S (NVO), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Mr. Miles D. White, Chairman & CEO (Age 63)
- Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 48)
- Mr. Brian J. Blaser, Exec. VP of Diagnostic Products (Age 53)
- Scott M. Leinenweber, VP of Investor Relations
- Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 52)
Has Abbott Laboratories been receiving favorable news coverage?
News articles about ABT stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Abbott Laboratories earned a coverage optimism score of 0.13 on Accern's scale. They also assigned media headlines about the healthcare product maker an impact score of 45.30 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are Abbott Laboratories' major shareholders?
Abbott Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.39%), Massachusetts Financial Services Co. MA (2.28%), Northern Trust Corp (1.49%), Diamond Hill Capital Management Inc. (0.60%), FIL Ltd (0.54%) and Dimensional Fund Advisors LP (0.54%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Which major investors are selling Abbott Laboratories stock?
ABT stock was sold by a variety of institutional investors in the last quarter, including Independent Franchise Partners LLP, Massachusetts Financial Services Co. MA, Flossbach Von Storch AG, Coho Partners Ltd., Swiss National Bank, American Century Companies Inc., Northern Trust Corp and Legal & General Group Plc. Company insiders that have sold Abbott Laboratories company stock in the last year include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.
Which major investors are buying Abbott Laboratories stock?
ABT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Montag & Caldwell LLC, Ceredex Value Advisors LLC, Eaton Vance Management, Summit Trail Advisors LLC, Mackay Shields LLC, CIBC World Markets Inc. and Franklin Resources Inc.. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Daniel J Starks, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.
How do I buy shares of Abbott Laboratories?
Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of ABT stock can currently be purchased for approximately $62.37.
How big of a company is Abbott Laboratories?
Abbott Laboratories has a market capitalization of $108.42 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.
How can I contact Abbott Laboratories?
Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.
MarketBeat Community Rating for Abbott Laboratories (ABT)
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Abbott Laboratories (NYSE:ABT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
17 Wall Street analysts have issued ratings and price targets for Abbott Laboratories in the last 12 months. Their average twelve-month price target is $68.4375, suggesting that the stock has a possible upside of 9.73%. The high price target for ABT is $80.00 and the low price target for ABT is $56.00. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.82 | 2.78 | 2.74 | 2.60 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $68.4375 | $67.0588 | $65.5556 | $56.5333 |
| Price Target Upside: | 9.73% upside | 13.99% upside | 4.30% upside | 1.37% upside |
Abbott Laboratories (NYSE:ABT) Consensus Price Target History
Abbott Laboratories (NYSE:ABT) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Abbott Laboratories (NYSE:ABT) Dividend Information
Abbott Laboratories pays an annual dividend of $1.12 per share, with a dividend yield of 1.80%. ABT's most recent quarterly dividend payment was Tuesday, May 15. The company has grown its dividend for the last 45 consecutive years and is increasing its dividend by an average of 6.40% each year. Abbott Laboratories pays out 44.80% of its earnings out as a dividend.
| Most Recent Dividend: | 5/15/2018 |
| Annual Dividend: | $1.12 |
| Dividend Yield: | 1.80% |
| Dividend Growth: | 6.40% (3 Year Average) |
| Payout Ratio(s): | 44.80% (Trailing 12 Months of Earnings)
39.16% (Based on This Year's Estimates)
34.78% (Based on Next Year's Estimates)
23.20% (Based on Cash Flow)
|
| Track Record: | 45 Years of Consecutive Dividend Growth |
| Frequency: | Quarterly Dividend |
Abbott Laboratories (NYSE:ABT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 2/16/2018 | quarterly | $0.28 | 1.85415114642828% | 4/12/2018 | 4/13/2018 | 5/15/2018 |
| 12/15/2017 | quarterly | $0.28 | 1.99% | 1/11/2018 | 1/12/2018 | 2/15/2018 |
| 9/15/2017 | quarterly | $0.2650 | 2.05% | 10/12/2017 | 10/13/2017 | 11/15/2017 |
| 6/9/2017 | quarterly | $0.2650 | 2.25% | 7/12/2017 | 7/14/2017 | 8/15/2017 |
| 2/17/2017 | quarterly | $0.2650 | 2.36% | 4/11/2017 | 4/14/2017 | 5/15/2017 |
| 12/9/2016 | quarterly | $0.2650 | 2.7% | 1/11/2017 | 1/13/2017 | 2/15/2017 |
| 9/15/2016 | quarterly | $0.26 | 2.48% | 10/12/2016 | 10/14/2016 | 11/15/2016 |
| 6/10/2016 | quarterly | $0.26 | 2.75% | 7/13/2016 | 7/15/2016 | 8/15/2016 |
| 2/19/2016 | quarterly | $0.26 | 2.66% | 4/13/2016 | 4/15/2016 | 5/16/2016 |
| 12/11/2015 | quarterly | $0.26 | 2.32% | 1/13/2016 | 1/15/2016 | 2/16/2016 |
| 9/17/2015 | quarterly | $0.24 | 2.22% | 10/13/2015 | 10/15/2015 | 11/15/2015 |
| 6/12/2015 | quarterly | $0.24 | 2% | 7/13/2015 | 7/15/2015 | 8/15/2015 |
| 2/20/2015 | quarterly | $0.24 | 2.03% | 4/13/2015 | 4/15/2015 | 5/15/2015 |
| 12/12/2014 | quarterly | $0.24 | 2.21% | 1/13/2015 | 1/15/2015 | 2/13/2015 |
| 9/11/2014 | quarterly | $0.22 | 2.07% | 10/10/2014 | 10/15/2014 | 11/15/2014 |
| 6/13/2014 | quarterly | $0.22 | 2.21% | 7/11/2014 | 7/15/2014 | 8/15/2014 |
| 2/21/2014 | quarterly | $0.22 | 2.26% | 4/11/2014 | 4/15/2014 | 5/15/2014 |
| 10/16/2013 | quarterly | $0.22 | 2.37% | 1/13/2014 | 1/15/2014 | 2/15/2014 |
| 9/12/2013 | quarterly | $0.14 | 1.61% | 10/10/2013 | 10/15/2013 | 11/15/2013 |
| 6/14/2013 | quarterly | $0.14 | 1.52% | 7/11/2013 | 7/15/2013 | 8/15/2013 |
| 2/15/2013 | quarterly | $0.14 | 1.61% | 4/11/2013 | 4/15/2013 | 5/15/2013 |
| 12/14/2012 | quarterly | $0.14 | 0.86% | 1/11/2013 | 1/15/2013 | 2/15/2013 |
(Data available from 1/1/2013 forward)
Abbott Laboratories (NYSE ABT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.74%
Institutional Ownership Percentage: 72.09%
Abbott Laboratories (NYSE ABT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/18/2018 | Daniel Gesua Sive Salvadori | Insider | Sell | 3,000 | $61.20 | $183,600.00 | 95,581 |  |
| 5/4/2018 | Sharon J Bracken | SVP | Sell | 2,150 | $58.56 | $125,904.00 | 43,990 | |
| 4/23/2018 | Jaime Contreras | Insider | Sell | 849 | $59.36 | $50,396.64 | 50,436 | |
| 3/9/2018 | Roger Bird | Insider | Sell | 8,262 | $62.75 | $518,440.50 | 58,574 | |
| 3/7/2018 | Jared Watkin | Insider | Sell | 3,000 | $61.19 | $183,570.00 | 68,215 | |
| 3/5/2018 | Sharon J Bracken | SVP | Sell | 2,100 | $60.27 | $126,567.00 | 44,790 | |
| 3/1/2018 | Jared Watkin | SVP | Sell | 996 | $58.87 | $58,634.52 | 69,511 | |
| 3/1/2018 | Sharon J Bracken | Insider | Sell | 1,053 | $58.93 | $62,053.29 | | |
| 3/1/2018 | Stephen R Fussell | EVP | Sell | 11,106 | $60.13 | $667,803.78 | 172,158 | |
| 2/27/2018 | Daniel J Starks | Director | Buy | 40,037 | $60.67 | $2,429,044.79 | 6,943,348 | |
| 2/20/2018 | Jared Watkin | SVP | Sell | 297 | $59.29 | $17,609.13 | 74,357 | |
| 2/20/2018 | Stephen R Fussell | Insider | Sell | 56,401 | $59.61 | $3,362,063.61 | 184,884 | |
| 1/31/2018 | Brian J Blaser | Insider | Sell | 27,733 | $62.26 | $1,726,656.58 | 156,587 | |
| 1/30/2018 | Stephen R Fussell | EVP | Sell | 13,313 | $62.84 | $836,588.92 | 152,343 | |
| 12/14/2017 | Daniel Gesua Sive Salvadori | Insider | Sell | 28,319 | $54.92 | $1,555,279.48 | 102,117 | |
| 12/6/2017 | Miles D White | Chairman | Sell | 276,886 | $54.41 | $15,065,367.26 | 3,677,913 | |
| 11/30/2017 | Sharon J Bracken | Insider | Sell | 2,188 | $56.12 | $122,790.56 | 25,618 | |
| 11/22/2017 | Alejandro D Wellisch | Insider | Sell | 2,153 | $55.86 | $120,266.58 | 10,256 | |
| 11/17/2017 | Brian J Blaser | Insider | Sell | 23,866 | $55.55 | $1,325,756.30 | 146,387 | |
| 11/14/2017 | Daniel Gesua Sive Salvadori | Insider | Sell | 71,157 | $55.00 | $3,913,635.00 | 144,955 | |
| 10/23/2017 | Daniel Gesua Sive Salvadori | EVP | Sell | 96,603 | $56.21 | $5,430,054.63 | 142,082 | |
| 9/26/2017 | Daniel Gesua Sive Salvadori | Insider | Sell | 62,460 | $52.95 | $3,307,257.00 | 113,426 | |
| 9/22/2017 | Jaime Contreras | Insider | Sell | 52,700 | $51.97 | $2,738,819.00 | 58,739 | |
| 8/16/2017 | Stephen R Fussell | Insider | Sell | 196,550 | $49.50 | $9,729,225.00 | 221,488 | |
| 8/1/2017 | Sharon J Bracken | Insider | Sell | 2,000 | $49.16 | $98,320.00 | 28,806 | |
| 7/27/2017 | Brian J Blaser | Insider | Sell | 15,000 | $50.00 | $750,000.00 | 143,154 | |
| 7/25/2017 | Hubert L Allen | Insider | Sell | 4,600 | $50.79 | $233,634.00 | 105,479 | |
| 6/15/2017 | Jared Watkin | Insider | Sell | 552 | $47.97 | $26,479.44 | 47,090 | |
| 6/8/2017 | Stephen R Fussell | Insider | Sell | 196,550 | $46.00 | $9,041,300.00 | 221,488 | |
| 4/27/2017 | Roger Bird | Insider | Sell | 5,600 | $43.82 | $245,392.00 | 51,313 | |
| 4/26/2017 | Joseph J Manning | Insider | Sell | 4,200 | $43.95 | $184,590.00 | 26,224 | |
| 3/1/2017 | Michael J. Warmuth | Insider | Sell | 3,851 | $45.39 | $174,796.89 | | |
| 2/23/2017 | Robert E Funck | VP | Sell | 25,500 | $45.50 | $1,160,250.00 | 117,579 | |
| 2/22/2017 | Roger Bird | Insider | Sell | 13,222 | $45.02 | $595,254.44 | 63,910 | |
| 2/21/2017 | Deepak S Nath | Insider | Sell | 319 | $44.98 | $14,348.62 | 58,471 | |
| 1/31/2017 | Heather L Mason | Insider | Sell | 35,700 | $40.77 | $1,455,489.00 | 100,189 | |
| 12/20/2016 | Brian J Blaser | Insider | Buy | 15,580 | $38.45 | $599,051.00 | 129,782 | |
| 12/14/2016 | Robert B Ford | Insider | Buy | 12,775 | $39.09 | $499,374.75 | 51,532 | |
| 11/10/2016 | Miles D White | Chairman | Buy | 121,456 | $40.45 | $4,912,895.20 | 2,802,558 | |
| 11/1/2016 | Sally E Blount | Director | Buy | 5,100 | $39.24 | $200,124.00 | 20,143 | |
| 9/26/2016 | Daniel Gesua Sive Salvadori | SVP | Sell | 815 | $41.71 | $33,993.65 | 59,791 | |
| 7/28/2016 | Stephen R Fussell | Insider | Sell | 41,500 | $45.00 | $1,867,500.00 | 196,467 | |
| 7/26/2016 | Michael J Warmuth | Insider | Sell | 26,800 | $43.49 | $1,165,532.00 | 81,811 | |
| 7/25/2016 | Miles D White | Chairman | Buy | 242,547 | $43.18 | $10,473,179.46 | 2,010,517 | |
| 7/25/2016 | Robert E Funck | VP | Sell | 26,800 | $43.08 | $1,154,544.00 | 111,819 | |
| 6/28/2016 | Hubert L Allen | EVP | Sell | 3,400 | $37.14 | $126,276.00 | 91,857 | |
| 6/15/2016 | Jared Watkin | SVP | Sell | 552 | $37.63 | $20,771.76 | 47,114 | |
| 6/1/2016 | Brian B Yoor | CFO | Sell | 565 | $39.49 | $22,311.85 | 50,182 | |
| 4/28/2016 | Deepak S Nath | SVP | Sell | 53 | $41.31 | $2,189.43 | 47,435 | |
| 3/31/2016 | Jaime Contreras | SVP | Sell | 462 | $41.78 | $19,302.36 | 47,667 | |
| 2/29/2016 | Brian B Yoor | CFO | Sell | 865 | $39.12 | $33,838.80 | 52,250 | |
| 2/29/2016 | Deepak S Nath | SVP | Sell | 793 | $39.27 | $31,141.11 | 48,364 | |
| 2/29/2016 | Robert B Ford | EVP | Sell | 1,706 | $39.28 | $67,011.68 | 62,495 | |
| 2/29/2016 | Robert E Funck | VP | Sell | 1,333 | $39.30 | $52,386.90 | 86,352 | |
| 2/22/2016 | Jared Watkin | SVP | Sell | 554 | $39.09 | $21,655.86 | 50,515 | |
| 2/16/2016 | Deepak S. Nath | SVP | Sell | 171 | $37.13 | $6,349.23 | 34,941 | |
| 12/16/2015 | Miles D. White | CEO | Sell | 438,000 | $46.00 | $20,148,000.00 | 1,394,153 | |
| 8/18/2015 | Stephen R. Fussell | EVP | Sell | 13,096 | $50.46 | $660,824.16 | 130,601 | |
| 4/27/2015 | Heather L Mason | EVP | Sell | 13,500 | $47.45 | $640,575.00 | | |
| 4/27/2015 | Roger Bird | SVP | Sell | 28,548 | $47.57 | $1,358,028.36 | | |
| 3/26/2015 | J. Scott White | SVP | Sell | 12,483 | $46.68 | $582,706.44 | | |
| 3/2/2015 | Jaime Contreras | SVP | Sell | 9,209 | $47.34 | $435,954.06 | | |
| 2/4/2015 | John M Capek | EVP | Sell | 34,292 | $45.66 | $1,565,772.72 | | |
| 11/25/2014 | Jaime Contreras | SVP | Sell | 51,600 | $44.07 | $2,274,012.00 | | |
| 10/29/2014 | Miles D White | CEO | Sell | 440,800 | $42.52 | $18,742,816.00 | | |
| 3/3/2014 | John Landgraf | EVP | Sell | 17,293 | $39.38 | $680,998.34 | 95,131 | |
| 3/3/2014 | Katherine Doyle | SVP | Sell | 6,639 | $39.01 | $258,987.39 | 47,525 | |
| 3/3/2014 | Robert Funck | VP | Sell | 1,413 | $38.97 | $55,064.61 | 62,926 | |
| 2/18/2014 | John Landgraf | EVP | Sell | 1,583 | $39.10 | $61,895.30 | 102,421 | |
| 1/29/2014 | Michael Warmuth | EVP | Sell | 11,430 | $36.21 | $413,880.30 | 40,487 | |
| 12/6/2013 | Jean-Yves Pavee | SVP | Sell | 5,855 | $37.46 | $219,328.30 | 30,901 | |
| 11/7/2013 | Stephen Fussell | EVP | Sell | 10,466 | $37.59 | $393,416.94 | 101,169 | |
| 10/30/2013 | Jaime Contreras | SVP | Sell | 25,368 | $36.85 | $934,810.80 | | |
| 6/7/2013 | Heather L Mason | SVP | Sell | 12,000 | $37.01 | $444,120.00 | | |
| 2/1/2013 | William A Osborn | Director | Buy | 10,000 | $33.86 | $338,600.00 | | |
(Data available from 1/1/2013 forward)
Abbott Laboratories (NYSE ABT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Abbott Laboratories (ABT) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 25 at 10:11 AM |
 | Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease
finance.yahoo.com - May 23 at 5:17 PM |
| Abbott's Investigational Tendyne™ Device for Mitral Valve Replacement Demonstrates Positive Outcomes at 30 Days in Global Study
finance.yahoo.com - May 23 at 8:08 AM |
| Brokerages Anticipate Abbott Laboratories (ABT) Will Announce Quarterly Sales of $7.76 Billion
www.americanbankingnews.com - May 23 at 4:53 AM |
| Five-Year Study Data Confirm Positive Outcomes for Patients When Abbott Diagnostic Tool Was Used to Guide Heart Stenting Decisions
finance.yahoo.com - May 22 at 8:10 AM |
| Abbott Laboratories (ABT) Insider Daniel Gesua Sive Salvadori Sells 3,000 Shares
www.americanbankingnews.com - May 21 at 7:52 PM |
| Shocking the Spine Offers an Alternative to Opioids
finance.yahoo.com - May 21 at 8:45 AM |
| $0.71 Earnings Per Share Expected for Abbott Laboratories (ABT) This Quarter
www.americanbankingnews.com - May 21 at 3:26 AM |
| Why Is Abbott (ABT) Up 2% Since Its Last Earnings Report?
finance.yahoo.com - May 18 at 5:18 PM |
| How Did Bausch + Lomb Perform in 1Q18?
finance.yahoo.com - May 15 at 5:22 PM |
| Will Abbott Laboratories (NYSE:ABT) Continue To Underperform Its Industry?
finance.yahoo.com - May 15 at 8:38 AM |
| Abbott Laboratories (ABT) Sees Significant Growth in Short Interest
www.americanbankingnews.com - May 14 at 1:33 AM |
 | Heart Device Procedure Is No Better Than Drug Therapy for Irregular Heartbeat: Study
www.wsj.com - May 12 at 5:19 PM |
| [$$] Heart Device Procedure Is No Better Than Drug Therapy for Irregular Heartbeat: Study
finance.yahoo.com - May 11 at 9:28 AM |
| Insider Selling: Abbott Laboratories (ABT) SVP Sells 2,150 Shares of Stock
www.americanbankingnews.com - May 8 at 8:16 PM |
| Is It Time To Buy Abbott Laboratories (NYSE:ABT)?
finance.yahoo.com - May 8 at 8:40 AM |
| How Analysts View Allergan after Its 1Q18 Earnings
finance.yahoo.com - May 8 at 8:39 AM |
 | How this pharma executive retired to help people around the world
www.marketwatch.com - May 7 at 5:17 PM |
 | Absolute Reports Fiscal 2018 Third Quarter Financial Results
www.businesswire.com - May 7 at 5:17 PM |
| A Brief Look at Abbott’s Alere Integration Progress and Recovery
finance.yahoo.com - May 7 at 5:17 PM |
| Abbott’s CRM Business Was Flat in 1Q18—What’s Ahead?
finance.yahoo.com - May 7 at 9:26 AM |
| Discussing Abbott’s Market Position and Growth Prospects in China
finance.yahoo.com - May 7 at 9:26 AM |
| $7.76 Billion in Sales Expected for Abbott Laboratories (ABT) This Quarter
www.americanbankingnews.com - May 5 at 2:50 AM |
| Despite Youth On Farm, Abbott Ventures Chief Avoids Spreading Manure
finance.yahoo.com - May 4 at 5:23 PM |
| ABT’s Medical Devices Business: A Key Growth Driver
finance.yahoo.com - May 4 at 8:26 AM |
| $0.71 EPS Expected for Abbott Laboratories (ABT) This Quarter
www.americanbankingnews.com - May 3 at 9:38 PM |
| Abbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter
finance.yahoo.com - May 3 at 5:17 PM |
| Abbott's XIENCE Sierra™ Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease
finance.yahoo.com - May 2 at 5:14 PM |
 | June 2019 Options Now Available For Abbott Laboratories (ABT)
www.nasdaq.com - April 30 at 5:24 PM |
| Abbott Laboratories (ABT) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 30 at 7:51 AM |
| Stocks Rally As Investors Like Facebook Results, AMD Powers Chips
finance.yahoo.com - April 26 at 5:13 PM |
| Abbott Laboratories (ABT) Insider Jaime Contreras Sells 849 Shares
www.americanbankingnews.com - April 25 at 7:28 PM |
| Abbott Laboratories Registered Organic Growth of 7% in 1Q18
finance.yahoo.com - April 25 at 5:13 PM |
| Citigroup Trims Abbott Laboratories (ABT) Target Price to $65.00
www.americanbankingnews.com - April 24 at 11:02 AM |
| Boston Scientific’s 1Q18 Revenues: What to Expect
finance.yahoo.com - April 24 at 8:32 AM |
 | BRIEF-Abbott Laboratories - Co, Sanquin Sign Multiple-Year Contract For Supply Of Primary Serological Equipment ...
www.reuters.com - April 23 at 5:03 PM |
| Sanquin Selects Abbott's "Alinity™ s" Solution for Blood and Plasma Screening
finance.yahoo.com - April 23 at 5:03 PM |
| Johnson & Johnson’s Revenues Continued to Rise in 1Q18
finance.yahoo.com - April 23 at 5:03 PM |
| The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive
finance.yahoo.com - April 23 at 9:00 AM |
| FY2021 Earnings Forecast for Abbott Laboratories (ABT) Issued By Gabelli
www.americanbankingnews.com - April 23 at 3:04 AM |
| Abbott Laboratories (ABT) to Post Q2 2018 Earnings of $0.71 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - April 23 at 1:54 AM |
| Abbott Laboratories (ABT) Forecasted to Earn Q2 2018 Earnings of $0.71 Per Share
www.americanbankingnews.com - April 23 at 1:54 AM |
| William Blair Weighs in on Abbott Laboratories' Q2 2018 Earnings (ABT)
www.americanbankingnews.com - April 23 at 1:54 AM |
| Abbott Laboratories (ABT) Rating Reiterated by BTIG Research
www.americanbankingnews.com - April 22 at 8:16 AM |
| Abbott Laboratories (ABT) Coverage Initiated by Analysts at BTIG Research
www.americanbankingnews.com - April 20 at 6:24 PM |
| Top Analyst Reports for Goldman Sachs, Abbott & Altria
finance.yahoo.com - April 20 at 5:20 PM |
| Abbott Extends Title Sponsorship of Abbott World Marathon Majors through 2023
finance.yahoo.com - April 20 at 5:20 PM |
| Abbott Laboratories (ABT) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 20 at 11:54 AM |
| Earnings Reaction History: Abbott Laboratories, 63.6% Follow-Through Indicator, 2.4% Sensitive
www.nasdaq.com - April 20 at 8:33 AM |
| FY2018 EPS Estimates for Abbott Laboratories Increased by William Blair (ABT)
www.americanbankingnews.com - April 20 at 8:32 AM |
Abbott Laboratories (NYSE:ABT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Abbott Laboratories (NYSE:ABT) Income Statement, Balance Sheet and Cash Flow Statement
Abbott Laboratories (NYSE ABT) Stock Chart for Saturday, May, 26, 2018
Loading chart…
